



I-MOVE
13th annual meeting

Virtual sessions between
16 and 30 September 2020

Draft agenda

Quick overview

Approximate Time (CEST)	16th Sept (Wednesday)	18th Sept (Friday)	28th Sept (Monday)	29th Sept (Tuesday)	30th Sept (Wednesday)
9:00-10:20			Session III: Influenza and COVID-19 co-circulation – experience from the Southern Hemisphere and subtropical climates		
14:00-16:45	Session I: 2019–20 influenza VE results from 5.1.2a studies		Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for 5.1.2a and beyond	Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for 5.1.2a and beyond	Session VII + VIII: Laboratory challenges + Influenza brand/type-specific studies
16:00-18:30		Session II: 5.1.2a 2019–20 influenza VE studies and approaches to COVID-19 surveillance		Session VI: Influenza vaccine and COVID-19	

Alternative time zones¹:

	9:00-10:20 CEST	14:00-16:45 CEST	16:00-18:30 CEST
WEST (5.1.2a 5.1.2a / 5.1.2a time)	8.00-9.30	13.00-15.45	15.00-17.30
EEST (5.1.2a 5.1.2a time)	10.00-11.30	15.00-17.45	17.00-19.30
5.1.2a	15.00-16.30	20.00-22.45	22.00-00.30 (+1)
5.1.2a	18.00-19.30	23.00-25.30	1.00 (+1)-3.30 (+1)
5.1.2a	1.00-2.30	6.00-8.45	8.00-10.30
5.1.2a	3.00-4.30	8.00-10.45	10.00-12.30
5.1.2a / 5.1.2a 5.1.2a	4.00-5.30	9.00-11.45	11.00-13.30

Detailed agenda

¹ Some of these times are at antisocial hours for some of our international colleagues. We will endeavour to record sessions so that colleagues can view the presentations at a more convenient time.

buiten verzoek

9:05 - 10:20 **Session III: Influenza and COVID-19 co-circulation – experience from the Southern Hemisphere and subtropical climates**

Moderators:

- Measuring influenza VE during SARS-CoV-2 co-circulation – results, challenges and lessons learnt, 15 min (5.1.2e)
- Measuring influenza VE during SARS-CoV-2 co-circulation – the experience from (5.1.2a) 15 min (5.1.2e)
- Influenza/ARI and COVID-19 cases in (5.1.2a) and timing of social distancing measures: results from surveillance data, 15 min (5.1.2e)
- Discussion, 30 min

Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (5.1.2e) and beyond

28th of September, Monday; 14:00–16:15 CEST

14:00 - 14:05 **Welcome and introduction** (ECDC, Epiconcept)

14:05 - 15:05 **Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (5.1.2e) and beyond**

Moderators:

- **Primary care: Adapting the influenza sentinel surveillance system to both COVID-19 surveillance and measuring influenza vaccine effectiveness**
 - The experience from (5.1.2a) 10 min (5.1.2e) (5.1.2e)
 - The experience from (5.1.2a) 10 min (5.1.2e) (5.1.2e)
 - The experience from (5.1.2a) 10 min (5.1.2e)
- Discussion, 30 min

15:05 – 15:15 Comfort break

15:15 – 16:15 **Session IV continued: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (5.1.2e) and beyond**

Moderators:

- **Primary care sentinel system challenges and approaches for the 2020–21 season: burden on health-care systems, influenza vaccine supply, surveillance, adaptation of platforms to measure COVID-19 interventions**
 - Reflections from (5.1.2a) 10 min (5.1.2e)
 - Reflections from (5.1.2a) 10 min (PHS team)
 - Reflections from the (5.1.2a) 10 min (the (5.1.2e) team)
- Discussion, 30 min

Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for (5.1.2e) and beyond

29th of September, Tuesday; 14:00–16:05 CEST

14:00-14:05 **Welcome and introduction** (ECDC, Epiconcept)

14:05 - 15:05 **Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for (5.1.2a) and beyond**

Moderators:

- **Hospital: Coping with COVID-19 surveillance and measuring 2019–20 influenza vaccine effectiveness**
 - Reflections from 5.1.2a 10 min 5.1.2e 5.1.2e
 - Reflections from 5.1.2a, 10 min 5.1.2e
 - Reflections from 5.1.2a 10 min 5.1.2e
 - Discussion, 30 min
- 15:05 – 15:15 Comfort break
- 15:15 – 15:55 **Session V continued: SARI surveillance plans for the future**
- Moderators:
- **SARI surveillance and respiratory pathogen vaccine effectiveness in the WHO 5.1.2a region, WHO/Euro, 10 min (WHO/Euro team)**
 - TBC, 10 min, ()
 - Discussion, 20 min
- 15:55 – 16:05 Comfort break (note that session VI follows on directly after the break)

Session VI: Influenza vaccine and COVID-19

29th of September, Tuesday; 16:05–16:45 CEST

- 16:05 - 16:45 **Session VI: Influenza vaccine and COVID-19**
- Moderators:
- Influenza vaccine does not increase the risk of coronavirus – results from 5.1.2a 10 min 5.1.2e
 - Association between influenza vaccine and COVID-19 at primary care level – preliminary results from 5.1.2a 10 min (5.1.2e
 - Discussion, 20 min

buiten verzoek